ENTITY
BeiGene

BeiGene (6160 HK)

303
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
20 Sep 2021 09:01

China Healthcare Weekly (Sep17) - A New Round of Rebalancing, Artificial Joints VBP, Genetic Testing

The article mainly analyzed the logic of volume-based purchase (VBP) and healthcare sector rebalancing, the results of centralized procurement of...

Logo
246 Views
Share
14 Sep 2021 09:15

InnoCare Pharma Ltd (9969.HK) - Risk of Becoming Mediocre

This article analyzed InnoCare in terms of its core product orelabrutinib, key product candidates in the pipeline, the competitive landscape, the...

Logo
228 Views
Share
14 Sep 2021 04:33

Asia Ex-Japan Positioning:  India & Tech at Record Highs

In this analysis, we provide a detailed overview of investor positioning among 96 active Asia Ex-Japan funds with combined AUM of $80bn.

Logo
168 Views
Share
05 Sep 2021 09:03

China Healthcare Weekly (Sep.3) - Price Reform of Medical Services, Medical Beauty, Functional Food

This article mainly analyzed the pilot plan for the price reform of medical services, new regulation on medical beauty advertisement, functional...

Logo
197 Views
Share
02 Sep 2021 09:02

Jiangsu Hengrui Medicine (600276.CH) - The Concerns and the Outlook

The article analyzed Hengrui in terms of its 2021/1H performance, pipeline, key products, industry policy impact, innovation trend, development...

Logo
271 Views
Share
x